TCR2 Therapeutics

Main focus: Next-generation iPSC-derived cell therapies

Company stage: Clinical

Diseases (gene editing): Solid tumours, haematological cancers

Genome editing tool: CRISPR

Funding stage: Public (NASDAQ:TCRR)

Location: Cambridge, MA, USA

Website: https://www.tcr2.com/

Pipeline: https://www.tcr2.com/our-pipeline/

Gene editing partnerships: Arbor Biotechnologies

TCR2 Therapeutics is developing next-generation cellular therapies to treat cancer. The company's technology is based on TCR Fusion Construct (TRuC) T cells that are engineered to recognise tumour cells. The company's engagement in the gene-editing space comes through its collaboration with Arbor Biotechnologies, giving TCR2 access to CRISPR-based gene-editing systems for the development of allogeneic cell therapies.

TCR2 Therapeutics

Your Latest CMN News

CRISPR/CasRx-Mediated Silencing of HTT Shows...

CMN Briefs

Jan. 14, 2025

Researchers in China report that targeting mutant HTT RNA with CRISPR/CasRx reduces the expression of diseased huntingtin protein and improves...

CMN Weekly (10 January 2025) - Your Weekly CRISPR...

CMN Weekly

Jan. 10, 2025

Some of the best links we picked up around the internet

Tune Therapeutics' HBV Epigenetic Silencer:...

CMN Clinical

Jan. 8, 2025

Tune Therapeutics has announced regulatory approval to begin a Phase 1b trial of its chronic hepatitis B therapy in Hong Kong, marking a strategic...

CRISPR Interference Reduces Antibiotic Resistance

CMN Briefs

Jan. 7, 2025

CRISPR interference (CRISPRi) emerges as a promising approach for re-sensitising multidrug-resistant bacteria to antibiotics while avoiding mutations...

CRISPR Repairs Limb-Girdle Muscular Dystrophy 2B...

CMN Briefs

Jan. 6, 2025

Researchers in Germany have developed a CRISPR-based strategy that successfully corrects a common mutation causing LGMD2B muscular dystrophy,...

CMN Weekly (20 December 2024) - Your Weekly CRISPR...

CMN Weekly

Dec. 20, 2024

Some of the best links we picked up around the internet